U.S.A approves a reagent for the early diagnosis of Alzheimer’s

The Medical Products Agency of USA (FDA) has approved a reagent that can help to identify Alzheimer’s disease in the early stages.

The radioactive product called flobetapir is designed to capture the characteristics of the disease, which would be visible by PET (positron emission tomography).

The company manufactures the substance in Philadelphia, Avid Radiopharmaceuticals. The early prognosis is considered the key to stop the evolution of the disease. (PLS)